MetaVia (MTVA) Investor presentation summary

Market opportunity and industry trends

• Obesity and MASH represent rapidly expanding global markets, with obesity projected to reach $80B–$130B and MASH $20B–$35B annually by 2030, driven by increasing prevalence and new drug approvals.

• Combination therapies are expected to become standard in MASH, increasing patient lifetime value.

• Major pharmaceutical companies have committed over $15 billion in obesity/MASH licensing deals in the past year, validating the sector's growth and strategic importance.

Pipeline and clinical progress

• DA-1726, a novel GLP1R/GCGR dual agonist, demonstrated -9.1% weight loss, -3.8 inch waist reduction, -0.22 HbA1c, and -23.7% liver stiffness at 48 mg in Phase 1, with mostly mild to moderate side effects.

• Tolerability optimization is ongoing with stepwise titration up to 64 mg; 16-week data readout expected in Q4 2026.

• Vanoglipel (DA-1241), an oral GPR119 agonist, met primary endpoints in Phase 2a for presumed MASH, showing liver benefit and significant HbA1c reductions.

• Vanoglipel demonstrated additive benefits in combination therapy in preclinical models and is being positioned for both monotherapy and combination use.

Competitive landscape and differentiation

• DA-1726 shows competitive efficacy and safety compared to other dual and triple agonists in development, with no discontinuations due to adverse events in Phase 1.

• Vanoglipel is well-tolerated, with no treatment-related discontinuations and a favorable safety profile in combination with other agents.

• Both programs target high unmet needs and are supported by strong intellectual property protection.